FibroGen Inc
General ticker "FGEN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $37.7M
FibroGen Inc does not follow the US Stock Market performance with the rate: -26.4%.
Estimated limits based on current volatility of 7.2%: low 0.37$, high 0.43$
Factors to consider:
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.53$, 1.96$]
- 2024-12-30 to 2025-12-30 estimated range: [1.03$, 3.09$]
Financial Metrics affecting the FGEN estimates:
- Negative: Non-GAAP EPS, $ of -2.55 <= 0.10
- Negative: Operating profit margin, % of -65.60 <= 1.03
- Negative: Operating cash flow per share per price, % of -83.93 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: negative Net income
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Negative: 0.14 < Interest expense per share, $ of 0.16
Short-term FGEN quotes
Long-term FGEN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $235.31MM | $140.73MM | $147.75MM |
| Operating Expenses | $523.84MM | $441.76MM | $429.57MM |
| Operating Income | $-288.53MM | $-301.02MM | $-281.81MM |
| Non-Operating Income | $-2.15MM | $6.16MM | $-5.05MM |
| Interest Expense | $2.15MM | $1.44MM | $15.53MM |
| R&D Expense | $387.04MM | $296.79MM | $282.86MM |
| Income(Loss) | $-290.68MM | $-294.87MM | $-286.87MM |
| Taxes | $0.35MM | $0.36MM | $-2.63MM |
| Other Income(Loss) | $1.01MM | $1.57MM | $0.00MM |
| Profit(Loss) | $-290.02MM | $-293.65MM | $-284.23MM |
| Stockholders Equity | $209.15MM | $-21.45MM | $-204.17MM |
| Inventory | $31.02MM | $40.44MM | $41.56MM |
| Assets | $773.82MM | $610.09MM | $423.53MM |
| Operating Cash Flow | $-82.23MM | $-145.93MM | $-315.02MM |
| Capital expenditure | $30.19MM | $38.74MM | $2.52MM |
| Investing Cash Flow | $-426.97MM | $89.12MM | $153.66MM |
| Financing Cash Flow | $-0.56MM | $46.78MM | $122.75MM |
| Earnings Per Share* | $-3.15 | $-3.15 | $-2.92 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.